Jonathan E. Lim, President, CEO at HALOZYME THERAPEUTICS INC (HALO), sold 20,000 shares at $8.15 ($164K) on 2007-07-31, disclosed to the SEC on 2007-08-02.
Scheduled sale ($164k) by President, CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.12 | 5,000 | $41K | 24.8% |
| 2 | $8.15 | 600 | $5K | 3.0% |
| 3 | $8.16 | 600 | $5K | 3.0% |
| 4 | $8.20 | 500 | $4K | 2.5% |
| 5 | $8.21 | 6,100 | $50K | 30.5% |
| 6 | $8.22 | 2,400 |
| $20K |
| 12.0% |
| 7 | $8.23 | 1,300 | $11K | 6.5% |
| 8 | $8.24 | 400 | $3K | 2.0% |
| 9 | $8.25 | 1,040 | $9K | 5.2% |
| 10 | $8.26 | 760 | $6K | 3.8% |
| 11 | $8.27 | 400 | $3K | 2.0% |
| 12 | $8.28 | 300 | $2K | 1.5% |
| 13 | $8.30 | 100 | $830 | 0.5% |
| 14 | $8.31 | 100 | $831 | 0.5% |
| 15 | $8.33 | 400 | $3K | 2.0% |
| Total | $8.20 avg | 20,000 | $164K | 100% |
| Filing → |
| ERAS | BUY | 2023-06-08 | $275K | — | Filing → |
| ERAS | BUY | 2023-03-28 | $284K | — | Filing → |
| ERAS | BUY | 2023-01-10 | $232K | — | Filing → |